Peptides
MOTS-c
Also called Mitochondrial-derived peptide
People explore MOTS-c for steadier energy, better workout stamina and metabolic health. The idea is appealing: a signal made by mitochondria, the cells’ energy machinery. The encouraging injection results come mainly from mice; measuring natural MOTS-c after exercise in people does not show that injecting it delivers the same benefits.
Dosage & duration
One supplier’s published subcutaneous example
Westwood exercise-mimetic row
Reported use · unapproved regimen- Dose
- 10 mg per injection
- How often
- 3 times weekly
- How long
- 12 weeks
A named commercial example, not a validated human regimen. Its surrounding clinical claims were not verified and are not adopted.
Sources: 2
Different online schedules are not evidence of a standard dose or safe cycle. Do not scale mouse mg/kg amounts into a personal dose.
Why people look into it
More energy for the day and the workout
That is the appeal of MOTS-c. Human injection benefits are not established by the exercise study often cited for it.
-
Day-to-day energy
People hope to feel less drained and manage ordinary activities more easily.
-
Workout stamina
Better training performance is a separate goal from simply feeling more energetic.
-
Metabolic health
Interest in blood-sugar control does not establish an alternative to diabetes care.
Why do people consider it?
Energy, exercise capacity and body composition are the practical attractions. MOTS-c is often discussed alongside weight-loss drugs, but it is not shown to suppress appetite or reproduce their clinical outcomes. Feeling more energetic is also not proof of better insulin sensitivity.
Can it replace exercise?
No human injection result establishes that. In the original exercise study, people cycled and researchers measured their own MOTS-c. The animals, not the human volunteers, received the peptide. That distinction matters when a page promises exercise benefits without exercise.
Making sense of the dose claims
The visible row preserves one supplier’s amount, frequency and course together. It does not make that schedule a consensus. The supplier’s wider claims about human trials and precise benefits should not be treated as verified evidence.
What should a useful result look like?
Distinguish day-to-day energy, repeatable workout performance and clinical metabolic measurements. None can be read from a plotted peptide curve. New or persistent fatigue should not automatically be attributed to low MOTS-c; it can have a different cause.
Model details: MOTS-c · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 12 h has no administered-human timing support in reviewed sources.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 12 hours
- Absorption half-life assumed
- 3 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Do not substitute the modified analog CB4211 or engineered R13A-MOTS-c for native MOTS-c.
- Endogenous biomarker concentrations cannot calibrate an entered exogenous dose.
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
Legacy 12 h has no administered-human timing support in reviewed sources.
mots-c-relative-timing-2026-10 · version 1
Common questions
Is MOTS-c a weight-loss injection?
It is investigated for metabolism, but the original mouse results do not establish how much weight people would lose by injecting it. It should not be presented as equivalent to semaglutide or tirzepatide.
Does exercise research prove injections work?
No. Measuring naturally occurring MOTS-c after exercise answers a different question from giving an injected product.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interest
- These are reasons people investigate it, not promised improvements.
- Weight loss
- Mouse metabolic findings cannot establish a human weight-loss result.
- What to compare
- An energy sensation and a measurable change in endurance are different outcomes.
- 1. Reynolds et al.: MOTS-c and physical capacity
Original research inspected: injected mice; human arm measured endogenous peptide after cycling, not a human injection trial.
- 2. Westwood Biotech MOTS-c monograph
Supplier table inspected for reported-use context only. Its molecular identity and human-efficacy claims contain discrepancies and are not adopted.
- 3. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
Legacy 12 h has no administered-human timing support in reviewed sources.
- 4. Reynolds et al.: MOTS-c, exercise and aging
Original study: injected MOTS-c enhanced physical capacity in mice; human arm measured naturally occurring MOTS-c after exercise.
- 5. Lee et al.: MOTS-c metabolic homeostasis
Original mitochondrial-derived peptide discovery and metabolic experiments in cells and mice.
- 6. FDA MOTS-c scientific review, July 2026
No human administration/PK studies identified for MOTS-c-related bulk substances; native MOTS-c and investigational analogues are not automatically equivalent.
Related compounds and examples
Related compounds
SS-31 (Elamipretide)
SS-31 / elamipretide: energy claims, Forzinity doses, Barth syndrome approval and what fatigue studies found.
Semaglutide Injection (Ozempic/Wegovy)
Semaglutide can reduce hunger and food intake, helping people lose weight. Wegovy injections are prescribed for weight management; Ozempic injections treat type 2 diabetes. Both are taken weekly, with gradual dose increases to help manage digestive side effects.
Semaglutide Oral (Rybelsus)
Oral semaglutide offers a daily tablet option for adults with type 2 diabetes who want to avoid injections. The morning routine matters: food, drink and other tablets affect absorption, and different semaglutide products cannot be compared milligram for milligram.